tech

December 16, 2025

OpenAI-backed biotech firm Chai Discovery raises $130M Series B at $1.3B valuation

Chai is building foundation models for drug discovery, specifically to predict interactions between molecules so they could be reprogramed for cures.

OpenAI-backed biotech firm Chai Discovery raises $130M Series B at $1.3B valuation

TL;DR

  • Chai Discovery raised $130 million in Series B funding at a $1.3 billion valuation.
  • The company's total funding now exceeds $225 million.
  • The funding round was led by General Catalyst and Oak HC/FT, with participation from multiple other investors including OpenAI.
  • Chai Discovery utilizes AI to accelerate drug development, focusing on predicting biochemical molecule interactions.
  • The startup's goal is to create a "computer aided design suite" for molecules.
  • Chai 2, their latest AI model, demonstrates improved success rates in designing custom antibodies from scratch.
  • CEO Josh Meier, formerly of Facebook and OpenAI, co-founded Chai Discovery in 2024.

Continue reading
the original article

Made withNostr